1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 2-2
&NA;,
Preview
|
PDF (876KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
2. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 3-3
&NA;,
Preview
|
PDF (757KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 4-4
&NA;,
Preview
|
PDF (745KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
4. |
Abciximab‘real world’ outcomes and prescribing patterns |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 5-6
Amanda Cameron,
Preview
|
PDF (1702KB)
|
|
摘要:
The platelet glycoprotein IIb/IIIa antagonist abciximab [‘ReoPro’] has well established efficacy for preventing complications in patients undergoing percutaneous coronary intervention. Therefore, the debate as to whether abciximab should be the standard of care in this indication focuses mainly on economic factors. At the 4th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, Virginia, US; May 1999], the cost effectiveness of abciximab was demonstrated in a US meta-analysis. In addition, several studies examined abciximab use in various ‘real-world’ settings, revealing practice patterns and clinical and economic outcomes in patients undergoing coronary interventions.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 7-7
&NA;,
Preview
|
PDF (764KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
6. |
Oprelvekin is promising in active Crohn's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 8-8
&NA;,
Preview
|
PDF (780KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
7. |
By pill or by patch, testosterone gets in on the act |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 9-10
Charles Bankhead,
Preview
|
PDF (1576KB)
|
|
摘要:
Various formulations of testosterone have yielded promising results in 3 recent clinical trials involving both women and men. In the first trial, transdermal testosterone improved sexual function and psychological well-being in women with sexual dysfunction after surgically-induced menopause. In the second trial, sustained-release implants of the synthetic testosterone analogue 7-alpha-methyl-19-nortestosterone (MENT) proved comparable to injectable testosterone for treatment of sexual dysfunction in men with hypogonadism. And finally, testosterone administered alone or in combination with levonorgestrel decreased truncal and total body fat in healthy men, contradicting the idea that the combination (under evaluation as a male contraceptive) induces bodyweight gain due to increased body fat. The findings were reported at the 81st Annual Meeting of the Endocrine Society [San Diego, US; June 1999].
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 10-10
&NA;,
Preview
|
PDF (773KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
9. |
Monoclonal antibody 5C8 prevents allograft rejection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 11-11
&NA;,
Preview
|
PDF (818KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
10. |
Improved cancer pain management with adjuvant therapy? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1197,
1999,
Page 12-12
&NA;,
Preview
|
PDF (743KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|